CoChat

Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation

Open access
Türk, T., Pietruck, F., Dolff, S., Kribben, A., Janssen, O.E., Mann, K., Philipp, T., Heemann, U., Witzke, O. · 2006 · American Journal of Transplantation
Cited by 98

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The purpose of this study was to investigate the use of the short-acting insulin secretion drug repaglinide in new-onset diabetes mellitus (NODM) after renal transplantation. Twenty-three Caucasian patients with NODM after renal transplantation were selected to receive repaglinide therapy and were followed for at least 6 months. A control group treated with rosiglitazone was chosen for comparison. Successful repaglinide treatment was defined as a significant improvement of blood glucose concentrations and HbA1c <7% in the absence of glucosuria and without the need for the addition of further anti-diabetic agents. After 6 months of treatment with repaglinide, 14 of the 23 patients were successfully treated. Mean HbA1c decreased from 7.6 +/- 0.6% to 5.8 +/- 0.6% in 14 patients treated successfully. In nine patients, hyperglycemia persisted, and they were switched to insulin treatment (HbA1c 8.5 +/- 2.9% at the beginning to 7.4 +/- 2.2%). Mean serum creatinine levels, cyclosporine A and tacrolimus blood levels did not change significantly following institution of repaglinide therapy. The rate of successful treatment and the degree of HbA1c decrease were similar compared to rosiglitazone-treated control patients. The data from our observational study indicate that repaglinide can be an effective treatment option in Caucasian patients with NODM after renal transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-6143.2006.01250.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 98

Metadata

Authors
Türk, T., Pietruck, F., Dolff, S., Kribben, A., Janssen, O. E., Mann, K., Philipp, T., Heemann, U., & Witzke, O.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2006-04
Volume
6
Issue
4
Pages
842-846
ISSN
1600-6135 (ISSN-L)
OpenAlex
W1990903078
Cited by
98
References
1
FWCI
4.75
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation. https://app.cochat.ai/papers/10.1111/j.1600-6143.2006.01250.x
The paper
Türk, T., Pietruck, F., Dolff, S., Kribben, A., Janssen, O. E., Mann, K., Philipp, T., Heemann, U., & Witzke, O. (2006). Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2006.01250.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.